Kas'ianenko I V, Asliaev L A, Bilynskiĭ B T, Geshelin S A, Golotiuk I A, Golotiuk S I, Gritsiak E S, Zhero S V, Koĭfman O G, Sidorik E P
Vopr Onkol. 1992;38(6):736-43.
Combination chemotherapy with cyclophosphamide, 5-fluorouracil, adriamycin and platinum was performed in 122 patients with stage III-IV squamous-cell cancer and adenocarcinoma of the lung. Control group included 84 cases of non-small-cell lung cancer treated with the same drugs except platinum. Ten patients with stage III disease received platinum-based combination chemotherapy and split-course radiotherapy in the total dose of 65-70 Gy. Complete or partial remission was obtained in 48.6 +/- 11.74% of stage III patients following three cycles of chemotherapy, with mean survival reaching 8.6 +/- 3.2 months. Survival in responders was 10.6 +/- 2.1 months. Chemoradiation treatment was associated with even higher survival (14.6 +/- 2.16 months). It is concluded that platinum be used in combination chemotherapy and chemoradiation treatment of the above categories of patients.
对122例Ⅲ-Ⅳ期肺鳞状细胞癌和腺癌患者进行了环磷酰胺、5-氟尿嘧啶、阿霉素和铂联合化疗。对照组包括84例接受相同药物(不含铂)治疗的非小细胞肺癌患者。10例Ⅲ期患者接受了以铂为基础的联合化疗和总剂量为65-70Gy的分段放疗。三个周期化疗后,Ⅲ期患者中有48.6±11.74%获得完全或部分缓解,平均生存期达8.6±3.2个月。缓解者的生存期为10.6±2.1个月。放化疗的生存期更高(14.6±2.16个月)。结论是铂可用于上述类型患者的联合化疗和放化疗。